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Influenssa- ja RS- virukset ovat merkittäviä ihmispatogeeneja, jotka aiheuttavat vuosittaisia 
epidemioita, ja influenssa A toisinaan pandemioita. Uusien molekyylibiologisten menetel-
mien kehitys on jatkuvassa nosteessa antiviraalisen hoidon kohdistamiseksi ja antibiootti-
en väärinkäytön vähentämiseksi. 
 
Tämän työn kokeellinen osuus suoritettiin Orion Diagnostica Oy:n tuotekehityslaboratori-
ossa ja työn tavoitteena oli pystyttää useita kaupallisia kvantitatiivisia käänteiskopiointi-
PCR (qRT-PCR) kittejä respiratory syncytial- virukselle (RSV) ja influenssaviruksille. Vali-
tuista qRT-PCR kiteistä oli tavoitteena valita sopiva vertailumenetelmä Orion Diagnostica 
Oy:n isotermaaliselle geenimonistusmenetelmälle, SIBA®:lle (Strand Invasion Based Amp-
lification). 
 
Vertailua varten pystytettiin kuusi kvantitatiivista yksiputkimenetelmään perustunutta qRT-
PCR kittiä. qRT-PCR kittien herkkyyttä mitattiin työtä varten eristetyillä virusnäytteillä, jotka 
kvantitoitiin ja joita käytettiin laimennossarjoina kokeissa. Myös kittien kantakattavuutta ja 
mahdollisia ristireaktioita testattiin muiden hengitystiepatogeenien kanssa NATtrol™ Flu 
Verification Panelista eritetyllä RNA:lla. Paneeli sisälsi yhteensä 16 erilaista virus- tai bak-
teeriperäistä mikrobikontrollia. Lopuksi, saatujen tuloksien perusteella qRT-PCR kittien 
suorituskykyä arvioitiin parhaimman kitin valitsemiseksi. 
 
Työhön valituista qRT-PCR kiteistä, RealStar® S&T Influenza RT-PCR Kit 3.0 ja RealS-
tar® RSV RT-PCR Kit 1.0 (altona Diagnostics) menestyivät parhaiten. Erot qRT-PCR kitti-
en välillä olivat tilastollisesti merkitseviä, esimerkiksi parhaimpien ja huonoimpien Ct arvo-
jen välinen ero oli jopa 67.6 %. Myös ristireaktioita esiintyi eri hengitystiepatogeenien välil-
lä. Pitää kuitenkin huomioida, että työn aikana jokaista käytettyä qRT-PCR kittiä käytettiin 
vain kerran ja näin ollen luotettavampien tuloksien saamiseksi olisi hyvä jatkaa testausta 
etenkin RealStar® RT-PCR kittien kanssa. Jatkossa kokeita voitaisiin myös tehdä näytteil-
lä, jotka on käsitelty käytettäväksi kylmäkuivatuissa SIBA® reaktioissa. 
 
 
Avainsanat qRT-PCR, influenza viruses, respiratory syncytial virus 
 Abstract 
  
Author(s) 
Title 
 
Number of Pages 
Date 
Jenni Dudek 
Set up and Selection of qRT-PCR Kits for Diagnosis of Human 
Respiratory Syncytial Virus and Influenza Viruses 
43 pages + 6 appendices  
23 November 2016 
Degree Bachelor of Health Care 
Degree Programme Biomedical Laboratory Science 
Specialisation option Biomedical Laboratory Science 
Instructor(s) 
 
Senior Lecturer Hannele Pihlaja 
Laboratory Specialist Jenna Flinck 
 
Respiratory syncytial virus (RSV) and influenza viruses are significant human pathogens 
causing annual epidemics and occasional pandemic outbreaks. Development of novel mo-
lecular diagnostics is of high importance in order to better and faster characterize the infec-
tion and use appropriate antiviral treatment and thus, prevent from misuse of antibiotics. 
 
Experimental part of this study was executed in Research and Development laboratory of 
Orion Diagnostica Oy. The aim of this study was to set up several commercially available 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) kits for diagnosis 
of RSV and influenza viruses. The aim was to select reference method for Orion Diagnos-
tica’s proprietary Strand Invasion Based Amplification (SIBA®) technology. 
 
During this study, six commercially available one-step qRT-PCR kits were compared. In 
order to measure sensitivity of the assays, viral RNA samples were extracted and quanti-
tated to be used as dilution series during the experiments. Inclusivity and possible cross-
reactivity were elucidated by challenging the reactions with other respiratory pathogens 
from extracted commercial NATtrol™ FLU verification panel. Panel contained 16 different 
viral or bacterial particles. Lastly, the performance of the qRT-PCR kits was evaluated in 
order to select the best kits. 
 
In conclusion, from the selected qRT-PCR kits, RealStar® S&T Influenza RT-PCR Kit 3.0 
and RealStar® RSV RT-PCR Kit 1.0 (altona Diagnostics) were the most successful based 
on the results. Variability between the results was significant, up to 67.6 % difference in Ct 
values was detected between the best and the worst kit. Moreover, cross-reaction between 
respiratory pathogens occurred. Although it is important to keep in mind, that during this 
study, all of the kits were used only once. Therefore, to obtain more reliable results, testing 
with the RealStar® RT-PCR kits should continue. Furthermore, the follow-up step would be 
to test the kits with samples processed to be used in freeze-dried SIBA® reactions. 
 
Keywords qRT-PCR, influenza viruses, respiratory syncytial virus 
 
 
 
   
TABLE OF CONTENTS 
 
Tiivistelmä 
Abstract 
Abbreviations 
1 Introduction 1 
2 Influenza viruses 2 
2.1 Structure of influenza viruses 2 
2.2 Influenza A life cycle 4 
2.3 Influenza A subtypes and epidemiology 4 
3 Human respiratory syncytial virus 5 
3.1 Structure and life cycle of RSV 5 
3.2 RSV subgroups and epidemiology 7 
4 Laboratory diagnosis of influenza and RSV 7 
5 Methods in molecular biology 9 
5.1 Nucleic acid extraction 9 
5.2 qRT-PCR 9 
5.3 qRT-PCR amplification 10 
5.4 SIBA® technology 13 
6 Aims of the study 14 
7 Materials and methods 15 
7.1 Sample material 15 
7.2 RNA extraction 17 
7.3 RNA quantitation 17 
7.4 qRT-PCR assays used in this study 18 
7.4.1 Genesig® Influenza B Virus Standard kit (Primerdesign) 20 
7.4.2 Genesig® Respiratory Syncytial Virus (all species) Standard Kit 
(Primerdesign) 21 
7.4.3 RealStar® S&T Influenza RT-PCR Kit 3.0 (altona Diagnostics) 21 
7.4.4 RealStar® RSV RT-PCR Kit 1.0 (altona Diagnostics) 22 
7.4.5 RIDA®GENE Flu&RSV (R-Biopharm) 23 
7.4.6 R-DiaFlu (Diagenode) 24 
7.5 qPCR instruments 25 
   
8 Results 25 
8.1 Quantitation 26 
8.2 Sensitivity and inclusivity 26 
8.3 Clinical samples 33 
8.4 Reliability of results 34 
9 Discussion 35 
References 40 
 
Appendices  
Appendix 1. Work protocol for RNA extraction from ATCC® samples and NATtrol™ 
FLU Verification Panel. 
Appendix 2. Work protocol for RNA extraction from clinical samples. 
Appendix 3. Content of the qRT-PCR kits: used reagents. 
Appendix 4. Quantitation of influenza B and RSV A and B: results and work protocols. 
Appendix 5. qRT-PCR work protocols for used kits. 
Appendix 6. qRT-PCR kit comparison table. 
 
 
  
   
Abbreviations 
 
ATCC® American Type Culture Collection 
cDNA Complementary DNA 
Ct Cycle threshold 
HA Hemagglutinin 
HEF Hemagglutinin-esterase-fusion 
RSV Respritatory syncytial virus 
IC Internal Control 
IVD In Vitro Diagnostics 
M1 Matrix protein 
M2 Membrane protein 
mRNA Messenger RNA 
NA Neuraminidase 
PA Polymerase activity protein 
PB1 Polymerase binding protein 1 
PB 2 Polymerase binding protein 2 
POCT Point-of-care tests 
RT Reverse transcription 
SIBA® Strand invasion based amplification 
qRT-PCR quantitative reverse transcription polymerase chain reaction 
vRNA Viral RNA 
WHO World Health Organization 
 
 
 
 
 
 
1 
  
1 Introduction 
 
Seasonal influenza, also known as the flu, is an acute viral infection caused by influen-
za viruses. This disease occurs globally and can affect all of the population making it a 
major health problem by causing annual epidemics and pandemics. Unlike common 
“cold”, and many other respiratory infections, influenza viruses can cause life-
threatening complications in high risk population. (WHO fact sheet N°211 2014.) 
 
Whereas seasonal influenza may cause severe illness to population of all ages, human 
respiratory syncytial virus (RSV) is the main cause of severe lower respiratory tract 
infections in infants and young children. Additionally, RSV is a significant problem in 
the elderly people. As the clinical presentation usually does not differ from other respir-
atory tract infections such as influenza, it is difficult to distinguish RSV from other res-
piratory viruses without further analysis. (WHO 2015.) To guarantee the control of epi-
demics and to provide adequate treatment for the infected patients, it is essential to 
develop rapid and reliable ways of diagnosing infections caused by RSV and influenza 
viruses (Templeton – Scheltinga – Beersma – Kroes – Claas 2003). As the influenza 
viruses rapidly evolve, it is necessary to find sufficiently sensitive methods allowing 
accurate detection and differentiation of RSV and influenza virus subtypes from other 
respiratory tract infections. 
 
Currently, patients with RSV and influenza infections can be treated with antiviral 
drugs. However, these treatments work optimally only when started within 30-36 hours 
after onset of the disease. (Stiver 2003; Mejias – Garcia-Maurino – Rodriguez-
Fernandez – Peeples – Ramilo 2016.) Therefore it is important to find reliable and fast 
detection method for the diagnosis for both viruses. Point-of-care testing (POCT) 
methods are rapidly evolving in molecular diagnostics and we are in time where 
“heavy” instruments, such as PCR can be soon replaced with faster, easier and more 
accurate detection methods. Today, there are plenty of POC tests based on immuno-
assays, which contain monoclonal antibodies. Rapidity is the advantage when these 
tests can generate result in 15 minutes or less, although the drawback is their sensitivi-
ty is relatively poor compared to PCR method. (Kirkwood 2016; Hurt et al. 2009.) 
 
The study was appointed by Orion Diagnostica Oy and the practical execution of this 
project was carried out during a ten-week practical training period, under the super-
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vision of Laboratory Specialist Jenna Flinck. Practical training took place in Orion Diag-
nostica Oy Research and Development laboratory located in Espoo. During the practi-
cal training, the purpose was to set up several commercially available quantitative re-
verse transcription polymerase chain reaction (qRT-PCR) kits, which are able to detect 
RSV and influenza viruses. The request was to find qRT-PCR assay with desired level 
of performance and the assays were assessed for their sensitivity, inclusivity, and se-
lectivity. Orion Diagnostica Oy has released the next analytes to their Orion GenRead 
Instrument, which are influenza A and B and RSV (SIBA® and Orion GenRead publica-
tions 2016). Tests are based on Strand Invasion Based Amplification (SIBA®) technol-
ogy which is Orion Diagnostica’s proprietary isothermal nucleic acid amplification tech-
nology. During development of new products it is required to have a reference method 
to compare to. 
 
2 Influenza viruses 
 
Influenza is a respiratory infection caused by influenza A, B and C viruses. Disease 
causes annual epidemics and high rate outbreak of infections, which can reach up to 5 
million people. Moreover, influenza A is characterized by a high number of deaths per 
annum, approximately 250 000 to 500 000. Only influenza A virus causes significant 
human disease and potential pandemics like Spanish flu in 1918 and swine flu in 2009, 
which was caused by influenza A H1N1 strain. Influenza B and C viruses usually cause 
milder disease. (WHO factsheet; Tille 2004:  836-38.) 
 
2.1 Structure of influenza viruses 
 
Influenza viruses belong to the family of Orthomyxoviridae and are enveloped and have 
negative-sense, single stranded and segmented ribonucleic acid (RNA) genome. Influ-
enza A and B viruses consist of eight unique genomic nucleocapsid segments, where-
as influenza C has only seven. Segmentation increases potential variability of the virus 
when each negative-sense RNA is associated with the nucleoprotein (NP) and the pol-
ymerase components such as, PB1, PB2, and PA. Nucleocapsids are protected with 
the M1 matrix protein (M1) which is covered by lipid bilayer envelope. Membrane pro-
tein (M2) forms an ion channel through the envelope and is lined by M1 protein, trans-
porting protons and promoting uncoating and viral release (Figure 1). (Murray – Rosen-
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thal – Pfaller 2013: 524-25; Hedman et al. 2011: 470-72.) The M1, M2 and NP proteins 
are type-specific and for example influenza B viruses have their unique BM2 and NB 
proteins (Hatta – Goto – Kawaoka 2004). 
 
 
Figure 1. Model of influenza A virus. HA = hemagglutinin, NA = neuraminidase, M1 = mat-
rix protein, M2 = membrane protein. (Modified from Hedman et al. 2013.) 
 
Influenza A and B viruses have two glycoproteins in their envelope, trimer shaped he-
magglutinin (HA) and tetramer shaped neuraminidase (NA). Influenza C virus has only 
one glycoprotein, hemagglutinin-esterase-fusion (HEF), which serves the functions of 
both the HA and the NA (Herrler – Dürkop – Becht – Klenk 1988). In case of the HA, 
two main functions can be distinguished, however the most important role is the facilita-
tion of the virus binding to the host cell surface receptor. Subsequently, the HA binds to 
the sialic acid structures of the cell surface receptors. Different HA types bind to specif-
ic sialic acids. Another important function of the HA is to help virus to uncoat after de-
livering the nucleocapsid into the host cell. Moreover, enzymatic activity of the NA also 
plays an important role in this process. NA participates in removal of sialic acid from 
the glycoproteins, which prevents clumping and helps to release virus particles from 
the surface of the infected cell.  
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2.2 Influenza A life cycle 
 
Viral RNA (vRNA) transcription and messenger RNA (mRNA) synthesis occur in a host 
cell. When HA molecule binds to the host cell glycoprotein receptor, virus gets an ac-
cess into the cell with receptor mediated endocytosis. Low pH of the endosomal envi-
ronment is crucial for occurrence of three dimensional changes in HA leading to fusion 
of viral and endosomal membranes. HA2 fusion peptide attaches specific structures of 
the virus surface to the endosome membrane causing holes in it. In low pH, M2 ion 
channels open and H+ protons influx into the virus. This influx causes further decrease 
of the viral pH. That pH change initiate decomposition of the M1 protein and subse-
quent release of the ribonucleoprotein (RNP) complexes to the cytoplasm as well as 
their transport to the nucleus. (Brooks – Carroll – Butel – Morse 2013: 581-83.) 
 
In the nucleus, the vRNA is synthetized to mRNA using transcriptase proteins (PA, 
PB1, and PB2). This is necessary to obtain methylated cap region of the RNA which is 
important sequence in order to bind to ribosomes. After transcription, the mRNAs are 
transported to the cytoplasm and translation occurs in ribosomes of endoplasmic re-
ticulum. Surface proteins like HA, NA and M2 are processed in the Golgi apparatus and 
endoplasmic reticulum and then transported to the cell membrane. Virus exits from the 
cell by budding. The NA of newly formed viruses has important role facilitating the re-
lease of virus from a host cell. (Das – Aramini – Ma – Krug – Arnold 2010; Samji 2009.)  
 
2.3 Influenza A subtypes and epidemiology 
 
Glycoprotein HA can be classified into 16 subtypes (H1-H16) and NA to 9 subtypes 
(N1-N9). With different combinations of HA and NA, influenza A viruses can be divided 
in subtypes such as H1N1 or H5N1. With the HA and the NA, influenza A virus can 
undergo major (shift) or minor (drift) antigenic changes which helps virus to avoid im-
mune system. Antibodies are specific for certain HA and NA types so rapid changing of 
antigens is necessary. This rapidity causes seasonal influenza and new vaccines have 
to be developed almost yearly. (Hedman et al. 2013: 473-74.) 
 
Influenza viruses A, B and C are all from one original form which was divided thou-
sands of years ago from each other. Influenza A occurs among humans, pigs, horses, 
sea mammals and birds of all kind. Based on laboratory tests, it has proven that only 
five influenza A virus subtypes has caused epidemics in human. These subtypes are 
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H8N8, H1N1, H2N2, H3N2 and H1N2. Influenza B on the other hand is almost only 
human virus with few exceptions. Classification of influenza A virus strains follows In-
ternational standards. It contains type, place of original isolation, date of original isola-
tion and antigen name. (Hedman et al. 2013: 473.) 
 
3 Human respiratory syncytial virus 
 
RSV is a significant lower respiratory pathogen dangerous especially in infants and 
young children. Moreover, RSV also causes infections in adults, even though clinical 
symptoms might be more variable and less distinctive. Most infants are infected before 
one year of age, and virtually everyone becomes infected by the age of two years. (Hall 
et al. 2009.) In a systematic review of Nair et al. (2010), RSV was estimated to be an 
important cause of the death in childhood from acute lower respiratory infection (ALRI) 
after pneumococcal pneumonia and haemophilus influenzae type b. RSV infections 
follow seasonal pattern causing epidemics during the winter season, although the virus 
appears throughout the year (Brooks et al. 2013: 600). 
 
3.1 Structure and life cycle of RSV 
 
The RSV virus was recovered 1957 and systematically it was classified in Pneumoviri-
nae genus of the Paramyxoviridae family. RSV has a negative sense, single-stranded 
and non-segmented RNA genome which is found in helical nucleocapsid. Nucleocapsid 
contains phosphoprotein (P) and large protein (L), which together are responsible for 
the polymerase activity of the virus. The virion is surrounded by the envelope contain-
ing two surface proteins, the binding glycoprotein (G) and fusion glycoprotein (F). The 
main function of the F protein is to promote fusion between the virion and the host 
plasma membrane. Glycoprotein G is an attachment protein, which replaces hemagglu-
tinin-neuraminidase (HN) of other Paramyxoviridae. Matrix protein (M) is lining the in-
side of the virion envelope (Figure 2). (Versalovic et al. 2011: 1357.) 
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Figure 2. Model of respiratory syncytial virus. G = larger glycoprotein (attachment protein), 
F = smaller glycoprotein (fusion protein), M = matrix protein, P = phosphoprotein, 
L = RNA polymerase. (Modified from Murray et al. 2013) 
 
Disease mechanism of RSV is similar to other members of the Paramyxovirus family; 
however there are so many differences in the structure that it is needed to classify RSV 
as a separate subgroup. RSV does not have hemagglutinin and neuraminidase like 
other paramyxoviruses, but there are many similar features in the structure. RSV en-
ters the host cell by the fusion with plasma membrane after binding with G protein on 
the cell surface glycolipids and F protein promoting the fusion. Replication occurs in a 
similar manner to other negative-strand RNA viruses, in the cytoplasm of a host cell. 
Once the virus is in the cytoplasm of a host cell the genome is released and tran-
scribed into mRNAs. The newly synthesized proteins are processed and mature virions 
leave the cell by budding without killing the cell. (Murray et al. 2013: 513-14.) 
 
The pathological effect of RSV is its ability to infect respiratory epithelium, causing cell 
damage and host’s immune response leading to the formation of lymphocytes, plasma 
cells and macrophages. Young children have already narrow airways and inflammation 
is decreasing ventilation causing wheezing and possibly asthma or allergic sensitiza-
tion later in life. (Hedman et al. 2011: 497-98; Bacharier et al. 2012.) 
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3.2 RSV subgroups and epidemiology 
 
Two antigenic subgroups of RSV can be distinguished, A and B. Subgroups can be 
identified on their variations in the structure of the glycoprotein G and other antigenic 
variability can occur with groups. During the annual epidemics, both groups can occur 
simultaneously, or other group dominates. Dominant subgroup usually alternates in 
cycles; therefore it varies yearly, which subgroup of RSV is more common. This yearly 
circulation, genetic and antigenic variation has been a challenge when attempting to 
develop functioning vaccine covering both subgroups. (Sullender 2000.) 
 
4 Laboratory diagnosis of influenza and RSV 
 
Diagnostic methods of RSV and influenza viruses have changed over time and new 
technologies are being developed (Figure 3). Typically, diagnosis of influenza is based 
on characteristic symptoms, season, and ongoing epidemic in the community. Distin-
guishing RSV and influenza viruses from other respiratory pathogens and identifying its 
type and strain give advantage to target correct treatment. Moreover, fast diagnostic 
methods are an essential contributor in infection control over pandemic strains. (Murray 
et al. 2013: 530-31.) 
 
 
Figure 3. Evolution of virus diagnostics. Timeline is showing the development of different 
technologies. PCR = polymerase chain reaction, HTS = high-throughput se-
quencing (also known as next generation sequencing). (Modified from Rasmus-
sen 2015.) 
 
Laboratory diagnosis of influenza can be accomplished by the evaluation of the pa-
tients’ immune response to the virus, detection of viral particles, isolation and growth of 
the virus, and establishing the viral components, such as antigens or genome (Murray 
et al. 2013). Influenza viruses are obtained from nasopharyngeal secretions as a naso-
pharyngeal aspirate or nasal/throat swab. Direct fluorescent antibody, polymerase 
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chain reaction, and viral culture are considered to be standard methods. However, viral 
culture is not rapid method and therefore, its clinical value is limited. Instead, qRT-PCR 
has been the benchmark for detection and quantification of respiratory RNA viruses as 
it offers more sensitive, specific, and rapid detection. (Templeton – Scheltinga – 
Beersma – Kroes – Claas 2003.) qRT-PCR can be used for diagnosis of a wider range 
pathogens and multiplex conventional qRT-PCR assays have been developed for sim-
ultaneous amplification of several viruses in a single reaction. Multiplex qRT-PCR as-
says are more cost-effective and faster when diagnosing different respiratory infections 
simultaneously. Moreover, the possibility to include multiple respiratory pathogens or 
for instance influenza A strains in one test is an advantage with multiplex qRT-PCR. 
(Ginocchio 2011.) 
 
Alongside with qRT-PCR, POC tests have been used in order to make rapid diagnosis 
within 30 minutes. Commonly, POC tests are immunoassays based on antigen detec-
tion and they can detect and distinguish between influenza A and influenza B infec-
tions. Therefore, these tests are only qualitative. Epidemic and pandemic strains of 
influenza pose ongoing risk; therefore World Health Organization (WHO) has issued 
recommendation on the use of rapid testing for influenza diagnosis. Their sensitivity is 
suboptimal, usually < 80 % and, based on studies, detection of novel influenza sub-
types is even lower. (Li-Kim-Moy et al. 2016; Petric – Comanor – Petti 2006.) Thus, in 
WHO recommendations, the both positive and negative results should be confirmed 
with immunofluorescent antibody test, culture or RT-PCR (WHO 2005). 
 
Advanced diagnostic point-of-care tests started to flow on market 2015 when first mo-
lecular point-of-care test was publicized and it is expected, that respiratory infections 
are likely to be among leading applications by 2020. Now, when manufacturers have 
found a way of simplifying PCR and other nucleic acid amplification methods by creat-
ing easy-to-use portable form assays, the diagnosis process will improve significantly.  
Eventually, in the nearest future, there will be point-of-care tests, which are sensitive, 
rapid and do not require sophisticated instruments. (Drain – Garrett 2015; Brendish – 
Schiff – Clark 2015.) 
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5 Methods in molecular biology 
 
5.1 Nucleic acid extraction  
 
Nucleic acid extraction and purification from different sample material is the previous 
step to the qPCR itself. The variability in qPCR is often related to the nucleic acid puri-
fication and its quality is one parameter that can have significant impact to the results 
of qPCR. Therefore, carefully chosen extraction method is probably the most important 
step in qRT-PCR. Low-quality RNA can influence further parameters of the analysis 
including, the quality of detection and quantitation. It is very important to ensure the 
reproducibility of the extraction steps, when comparing biological samples. (Fleige – 
Pfaffl 2006.) 
 
In this study, silica based nucleic acid purification method was used for nucleic acid 
extraction. Boom et al. introduced 1990 developed simple, rapid and cheap nucleic 
acid purification method which is based on vRNA binding to silica membrane in the 
presence of chaotropic agents and the lysates create optimal salt and pH conditions to 
ensure that protein or other contaminants are not retained on the silica membrane. 
Contaminants that might have remained on the sample are removed in two wash-
steps. After wash-steps, pure vRNA is eluted in small volume of a low-salt buffer or 
RNAse-free water. (Boom et al. 2009.) 
 
5.2 qRT-PCR 
 
The quantitative real-time polymerase chain reaction (qPCR) is based on original PCR 
which relies on thermal cycling to amplify single copy of a piece of DNA to generate 
millions of copies of a specific DNA sequence (Madigan – Martinko – Bender – Buckley 
– Stahl 2015: 343). In original PCR, at the end of the amplification process, the product 
can be separated on a gel electrophoresis for detection of this specific product (Brown 
2006: 57). In qPCR this step can be avoided since quantitation of the amount of the 
target leads to the immediate detection of the product in a single tube. Therefore, 
qPCR lowers the contamination risk caused by opening the tubes for post-PCR manip-
ulation. Another advantage of the qPCR compared to gel based analysis is that it re-
quires less time to be performed and it is able to generate quantitative results. qPCR 
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uses fluorescent probes to monitor the amplification process and the fluorescent signal 
reflects the amount of product formed. (Madigan et al. 2015: 345-46.) 
 
Quantitative reverse-transcriptase polymerase chain reaction, qRT-PCR, is a quantita-
tive real-time gene expression analysis method that allows amplification of a single-
stranded RNA sequence. First RNA is converted to complementary DNA (cDNA) with 
reverse-transcriptase, which can use RNA as a template. qRT-PCR can be performed 
as a one-, or two-step method. The one-step qRT-PCR combines the reverse transcrip-
tion (RT) to cDNA and PCR reaction in a simple, closed tube protocol. Therefore, the 
tube contains two enzymes. The first enzyme, reverse transcriptase, is an activation 
enzyme producing complementary cDNA strand. Temperature increase to 95°C inacti-
vates the RT enzyme and simultaneously activates the DNA polymerase, which starts 
the amplification of the PCR products. (Nolte – Hill 2011: 1272-73.) 
 
Using the one-step method is advantageous in various ways, for example it saves time 
when it is faster to set up in single tube and it reduces margin of error. Errors is re-
duced when there is less handling of the samples, less pipetting and less possibilities 
for contamination during the procedure. However, disadvantage for the one-step meth-
od is that it might affect to qRT-PCR efficiency when the cDNA might not be propor-
tional or linear in each standard. (Wacker – Godard 2005.) 
 
5.3 qRT-PCR amplification 
 
Current detection methods are based on changes in fluorescence. In the qRT-PCR the 
product is fluorescently labelled and amount of fluorescence released during amplifica-
tion is monitored during the whole PCR process. Moreover, there is a positive correla-
tion between the initial number of RNA molecules in the sample and the increase of 
fluorescence during the PCR cycles. If a sample contains more targets, the fluorescent 
will be detected earlier. (Nolte – Hill 2011: 1274-76.) 
 
There are several ways in which the amplified RNA is fluorescently labelled (probe- or 
none-probe chemistries) but in this study, all of the commercial qRT-PCR kits are 
based on TaqMan® Probe-based chemistry (Figure 4). In TaqMan® chemistry, after 
denaturation, an oligonucleotide probe is assembled. Fluorescent reporter dye is at-
tached on the 5' end and a quencher dye on the 3' end of the probe. When the probe is 
intact, the reporter dye emission is quenched completely. If the target sequence is pre-
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sent, the DNA polymerase cleaves the reporter dye from the probe with the activity of 
Taq DNA polymerase. When reporter dye is separated from the quencher dye, reporter 
dye signal starts to increase. Fluorescent intensity is directly proportional to the number 
of molecules released during that cycle. (Bustin – Mueller 2005; Kubista 2006: 98-103). 
 
 
Figure 4. TaqMan principle. Reporter dye (fluorophore) = Red, Quencher dye = Green. 
(Modified from Wang et al. 2006.) 
 
During the early cycles of qRT-PCR, there is very little of fluorescence and the signal is 
weak. Therefore, it cannot be distinguished from the background. Theoretically, after 
each cycle the amplification product doubles and for that reason, the fluorescence in-
creases exponentially. After some time, exponential growth reaches plateau due to the 
lack of components required for the reaction to occur. (Kubista et al. 2006: 98) In order 
to be able to measure amount of amplified target, threshold line can be set to the qPCR 
programme manually or it can be calculated automatically. Threshold is set above the 
baseline, which defines the average background where no significant fluorescence is 
detected during the early cycles. When the fluorescent signal has increased significant-
12 
  
ly and transcended the threshold, the point is defined as the Ct value (Figure 5). (Ku-
bista et al. 2006: 98-101.) 
 
 
Figure 5. Example of threshold, which defines the Ct value of the target when increase of 
the reporter dye crosses the threshold. (Modified from qPCR guide.) 
 
The determination of the amount of the viral RNA can be performed by absolute quanti-
tation, where the exact number of copies of target is calculated. Absolute quantitation 
requires a standard sample of known concentration of RNA molecules and it can be 
constructed using serial dilution of known standard sample. After amplification, by the 
Ct values of the serial dilution, logarithmic standard curve can be generated (Figure 6). 
Quantitation of the target RNA is calculated by comparing the Ct values between the 
standard samples and the target amplification product. (Mackay et al. 2002; Bustin et 
al. 2005.) 
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Figure 6. qRT-PCR standard curve. qRT-PCR response curves shown in logarithmic scale 
for six standard samples. (Modified from Tourinho et al. 2015.) 
 
5.4 SIBA® technology 
 
SIBA® (Strand Invasion Based Amplification) technology is an isothermal (the tempera-
ture never increases over 40 °C) nucleic acid amplification method developed by Orion 
Diagnostica Oy. The technology is based on the recombinase-dependent incorporation 
of a single-stranded invasion sequence into a complementary region of a DNA. SIBA® 
is in many aspect superior to qRT-PCR, which is used in similar applications. For ex-
ample, unlike qRT-PCR, SIBA does not require thermal cycling and most importantly, it 
can be performed using standard laboratory equipment, therefore does not require ex-
pensive and sophisticated laboratory tools. It is well known, that analytical methods of 
this type, are prone to non-specific amplification, which reduces their sensitivity. Im-
portantly, in case of SIBA, this issue is virtually non-existent, making it sensitive for a 
single target molecule. SIBA® is a real-time monitoring system, which utilizes fluores-
cent dyes and increases quality of the analysis. (Hoser – Mansukoski – Morrical – 
Eboigbodin 2014.)  
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For the detection of vRNA targets, reverse transcription SIBA (RT-SIBA) was devel-
oped to diagnose vRNA targets within point-of-care or central laboratory settings. RT-
SIBA is one step method where a reverse transcriptase enzyme converts single-
stranded RNA into cDNA, which can be amplified and detected by SIBA under isother-
mal reaction conditions. (Eboigbodin et al. 2016). 
 
6 Aims of the study 
 
Currently, Orion Diagnostica Oy is in the process of the publishing new analytes, influ-
enza A and B and RSV to the Orion GenRead® platform (Orion Diagnostica Oy). The 
technology used in platform is based on the isothermal nucleic acid amplification tech-
nology, SIBA® (Strand Invasion Based Amplification). During the process of develop-
ment and validation it is needed to have reference method. The aims of this study were 
to set up and test several commercial qRT-PCR kits and to select optimal assay to 
work as a reference method for SIBA®. 
 
Main research questions of this study are:  
 
• to find a reliable and sensitive reference qRT-PCR assay for tests based on SI-
BA® technology. 
• to test whether selected assays also detect influenza virus subtypes.  
• to investigate whether cross reactions between viruses occur. 
 
All of these questions will be addressed and clarified during the progress of the studies. 
 
The study was supervised by Laboratory Specialist Jenna Flinck from Orion Diagnosti-
ca Oy, as well as by Senior Lecturer Hannele Pihlaja from Metropolia University of Ap-
plied Sciences. Experimental part of this project was conducted at Orion Diagnostica 
Oy R&D laboratory in Espoo.  
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7 Materials and methods 
 
For this study, viral RNA was extracted from selected sample population. Extracted 
viral RNA was then quantitated to be used with the qRT-PCR kits. After the set up of 
the qRT-PCR kits chosen for this study was accomplished, and results were obtained, 
the kits were evaluated based on their performance. These steps are shown schemati-
cally in Figure 7 and described in detail below. 
 
 
Figure 7. Workflow of the experimental part of the study. 
 
7.1 Sample material 
 
RSV and influenza virus strains (RSV subgroup A, RSV subgroup B, influenza A, influ-
enza B) were obtained from the American Type Culture Collection (ATCC®). Table 1 
shows strains that were used in this study. 
 
Table 1. Respiratory pathogens from ATCC® used in this study. 
 
  Strain LOT  
 RSV A ATCC® VR-1540™ A2 60439286  
 RSV B ATCC® VR-1400™ B WV/14617/85 49609416  
 Influenza A ATCC® VR-1736™ A/Virginia/ATCC1/2009 59335953  
 Influenza B ATCC® VR-1813™ B/Massachusetts/2/2012 62482427  
 
Later, extracted RNA from ATCC® influenza A VR-1540™ was replaced with Ampli-
run® influenza A H1 RNA Control (Vircell). Basal concentration of the kit 14100 cp/µL 
was diluted to final concentration of 10000 cp/µL. 
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To be able to establish the inclusivity of the assays and possible cross-reactions be-
tween respiratory pathogens, they were performed using a set of purified and intact 
viral and bacterial targets of commercially available NATtrol™ FLU Verification Panel 
(ZeptoMetrix Corporation), which mimics clinical specimen. Samples included to the 
panel should give positive results for different respiratory pathogens including, Rhinovi-
rus, M. Pneumoniae, N. Meningitidis, RSV B, RSV A, Echovirus, Parainfluenza 1, Influ-
enza A 2009 H1N1 strains New Cal and Brisbane, Influenza A H3N2 strains Wisconsin 
and Brisbane, Influenza A H1N1 09 strains Canada and NY, Influenza B strains Florida 
and Malaysia, Coxsackievirus. For details see Table 2. 
 
Table 2. NATtrol™ FLU Verification Panel (ZeptoMetrix Corporation) samples used in this 
study in order to determine inclusivity and cross-reactivity of the qRT-PCR kits. 
 
 Panel Member Strain  
 Rhinovirus 1A NA  
 M.Pneumoniae M129  
 M. Meningitidis Serogroup A NA  
 Respiratory Syncytial Virus B CH93(18)-18  
 Respiratory Syncytial Virus A NA  
 Echovirus Type 30 NA  
 Parainfluenza virus Type 1 NA  
 Influenza A H1N1 A/NewCaledonia/20/99  
 Influenza A H3N2 A/Wisconsin/67/05  
 Influenza A 2009 H1N1 A/Canada/6294/09  
 Influenza A H1N1 A/Brisbane/59/07  
 Influenza A H3N2 A/Brisbane/10/07  
 Influenza A 2009 H1N1 A/NY/02/09  
 Influenza B B/Florida/02/06  
 Influenza B B/Malaysia/2506/04  
 Coxsackievirus Type A9 NA  
 
Later, actual clinical samples were included to the qRT-PCR assays (Table 3). Sam-
ples were either nasopharyngeal swabs or aspirates of influenza A and B from FIMLAB 
2014 and RSV A and B (2007-2008) from Orion Diagnostica Oy own sample collection. 
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Table 3. Clinical samples used in this study. 
 
 Clinical sample Pathogen  
 1 Influenza A  
 2 Influenza A H1N1  
 3 Influenza A  
 4 Influenza A  
 5 Influenza A H1N1 (weak positive)  
 6 Influenza B  
 7 RSV  
 8 RSV  
 9 RSV  
 10 RSV  
 
7.2 RNA extraction 
 
RNA was extracted with the commercially available QIAamp® Viral RNA Mini Kit (Qi-
agen). QIAamp® Viral RNA Mini Kit (Qiagen) uses Guanidinium isothiocyanate (GITC) 
- silica method. RNA extraction was carried out according to manufacturer’s instruction 
with Spin Protocol, except for the step two where only 40 µL of sample (ATCC®, NAT-
trol® Flu Verification Panel) was used and rest of the volume (100 µL) was replaced 
with phosphate-buffered saline (PBS) to obtain total volume of 140 µL. 60 µL of the 
clinical samples was used and diluted into 80µL of PBS to obtain volume of 140 µL. 
This was done to save valuable sample material. Despite of the dilution, all of the sam-
ples contained large quantities of vRNA (cp/µL). After the two wash-steps, QIAamp 
Mini columns are instructed to perform one extra centrifugation at full speed for one 
minute. Full protocols are shown in the Appendix 1 and 2. After elution, purified viral 
RNA was collected to 1.5 ml microsentrifuge tubes and stored in - 70°C. 
 
7.3 RNA quantitation 
 
Genesig® qRT-PCR Pathogen kits (Primerdesign) contains a positive control template, 
which is quantitated. Therefore, it can be then used to generate standard curve. The 
determination of the amount of the pure RNA was performed by absolute quantitation, 
where the exact number of copies of interest was calculated. Absolute quantitation re-
quires a standard curve of known number of copies and it can be constructed using 
several standards. The linear range of quantitation of the one-step qRT-PCR assay for 
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genomic RNA can be determined using 10-fold serial dilutions of the positive control 
template ranging from 20 to 2 × 105 copies/µL to determine the end-point limit of detec-
tion and the linearity of the assay (Table 4). Reason for choosing this quantitative 
method was that the qRT-PCR assay is more sensitive than fluorometric quantitation 
and less expensive than commercially available quantitated Vircell AMPLIRUN® RNA 
controls. 
 
Table 4. Standard curve dilution series of Genesig® qRT-PCR pathogen kits positive con-
trol template in order to quantitate extracted vRNA from ATCC® samples. 
 
 
Standard curve 
Copy number per 
µL 
 
 Tube 1 Positive control (RED) 2 x 10
^5
  
 Tube 2 2 x 10
^4
  
 Tube 3 2 x 10
^3
  
 Tube 4 2 x 10
^2
  
 Tube 5 20  
 
After quantitation, copy number of RNA samples extracted from ATCC® samples was 
known and samples were diluted to the desired concentration of 10 000 cp/µL and ali-
quoted into individual 10 - 30µl volumes before storage in - 70°C until used. 
 
7.4 qRT-PCR assays used in this study 
 
Six kits based on detection of RSV and influenza viruses and commercially available in 
Finnish market in 2016 were tested. In order to find an optimal reference method for 
SIBA® technology, several values were taken into consideration when selecting com-
mercial qRT-PCR assays for this study. Ideal assay would be done only in one-step, 
which would save time on pipetting steps when RT and qPCR reactions are performed 
in same tube and the cross-contamination risk between RT and qPCR steps would be 
reduced to minimum. Also SIBA® technology has a one-step RT-SIBA method. It is 
desired that same assay would be able to detect multiple targets in single PCR experi-
ment. In the current study, the targets were RSV and influenza viruses. Sensitivity and 
inclusivity should be high to meet the standards of Orion Diagnostica Oy requested for 
their purposes. Other parameter used to evaluate the assays in this study was to de-
termine their usability with clinical diagnostics in EU (CE marked) and/or USA (FDA 
approval). 
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The qRT-PCR amplifications were carried out according to the manufacturer’s instruc-
tions. For inclusivity testing, each sample was tested once with duplicate sample per 
used assay. All qRT-PCR kits, except Genesig® Pathogen kits (Primerdesign), includ-
ed positive controls and required reagents to perform qRT-PCR. Negative controls 
(RNAse free water) were used in each reaction. Genesig® Pathogen kits (Primerde-
sign) required separate Oasig™ OneStep qRT-PCR Master Mix (Primerdesign). 
 
Despite all used qRT-PCR kits included different reagents, different protocols were 
followed while preparing the Master Mix and during amplification process, the laborato-
ry working routine was carried out under similar conditions. All of the used reagents 
and samples were handled on ice or cold blocks throughout the processing. Only nec-
essary amount of samples or reagents were unfrozen to each qRT-PCR setup to avoid 
excessive freeze-thawing. Work was carried out using good laboratory practises and 
following unidirectional workflow in three different laboratory facilities (Figure 8). 
 
 
Figure 8. The workflow in PCR laboratory. Unidirectional workflow continues in one direc-
tion only from pre-PCR to post-PCR. 
 
In the first laboratory the reagent preparation room, the PCR Reaction Mix was pre-
pared and pipetted into 96-well PCR plate. Then, the plate was covered and moved to 
a template laboratory where samples and controls were added. Lastly, ready 96-well 
PCR plate was carried to the amplification room, where PCR instruments where 
housed. Before placing the 96-well PCR plate to qRT-PCR instrument, it was briefly 
centrifuged. 
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7.4.1 Genesig® Influenza B Virus Standard kit (Primerdesign) 
 
This assay is designed for the detection of influenza B. The manufacturer assures 
more than 95% efficiency and detection of less than 100 copies of target template un-
der optimal PCR conditions. A specific influenza B primer and probe mix, which is 
based on the TaqMan® principle, were provided with the kit. Fluorescent data can be 
detected through the FAM channel. Assay is not CE marked nor FDA approved, there-
fore, it can be used for research purposes only. 
 
In this assay there is possibility to use either one-, or two-step qRT-PCR protocol, but 
the one-step method is recommended. Kit also provides positive control template, 
which can be used to generate standard curve of influenza B copy number /CT value. 
At least one positive control template should be also included in each qRT-PCR test to 
control the primers and probes for detecting the target influenza B. In this study, there 
were always two positive controls as well as negative control in each run. 
 
The work was performed according to the manufacturer’s instructions (PrimerdesignTM 
2016). Oasig™ OneStep qRT-PCR Master Mix (Primerdesign) was used. Amplification 
protocol can be seen in the Table 5 and full work protocol in the Appendix 5. Extracted 
active influenza B samples (ATCC) were diluted in a series from 1:10 up to 1:10000 
dilutions. PCR instrument used in this experiment was Applied Biosystems™ ViiA™ 7 
platform (Thermo Fisher Scientific Inc). 
 
Table 5. Amplification protocol used with Genesig® Influenza B Virus Standard kit (Pri-
merdesign). 
 
 Step Time Temp (°C) Cycles  
 Reverse transcription 10 min 55 1  
 Enzyme activation 2 min 95 1  
 Denaturation 10 s 95 
50 
 
 Data collection 60 s 60  
 
Genesig® human influenza B Virus Standard kit (Primerdesign) was only used for its 
feature to be able to create standard curve and use it to quantitate extracted vRNA 
(ATCC® samples) for this study.  
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7.4.2 Genesig® Respiratory Syncytial Virus (all species) Standard Kit (Primerdesign) 
 
Assay is designed to detect both, A and B RSV subgroups and exclude closely related 
human Metapneumoviruses. Assay provides RSV specific primer and probe mix, which 
are based on the TaqMan® principle. Although, all of the RSV types can be detected, 
the method does not provide specification of the types. Fluorescent data can be de-
tected through FAM channel. Under optimal PCR condition, the manufacturer assures 
more than 95% efficiency and detection of less than 100 copies of target template. 
 
Genesig® Respiratory Syncytial Virus (all species) Standard Kit (Primerdesign) also 
offers possibility to carry out the experiment both with one-, or two-step protocol and for 
copy number determination assay contains a positive control template. The work was 
performed according to the manufacturer’s instructions (PrimerdesignTM 2016). Full 
work protocol can be seen in the Appendix 5 and amplification protocol is identical to 
Genesig® influenza B virus Standard kit (Primerdesign) (Table 5).  
 
First phase was to quantitate obtained vRNA of the ATCC® RSV A and B samples. 
Quantitation was performed with standard curve dilution series (Table 4) and ATCC® 
samples were diluted from 1:10 up to 1:10000 dilutions. Following determination of the 
ATCC® samples, the assay was used to perform qRT-PCR with dilution series of RSV 
A and B (ATCC®), set of NATtrol™ FLU Verification Panel (ZeptoMetrix Corporation) 
samples and the clinical samples 7-10 can be seen in the Appendix 5 and used sam-
ples in Table 13. In each amplification setup, two positive and negative controls were 
included into each run in order to verify, that the primers and probes are working cor-
rectly and to test, that the reagents have not become contaminated while setting up the 
protocol. 
 
7.4.3 RealStar® S&T Influenza RT-PCR Kit 3.0 (altona Diagnostics) 
 
The RealStar® Influenza S&T RT-PCR Kit 3.0 (altona Diagnostics) is able to detect 
and distinguish seasonal influenza A and B viruses as well as pandemic H1N1 strain. 
The assay contains Internal Control (IC) to identify possible qRT-PCR inhibition and/or 
work as a sample preparation procedure control. The probes were labelled with fluo-
rescent reporter and quencher dyes specific for their respective target. Fluorophore 
Cy5 was specific for seasonal influenza A, FAM for pandemic influenza A H1N1, ROX 
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for influenza B and JOE for IC. The sequences of the primers and probes are listed 
below in the Table 6: 
 
Table 6. Primers and probes used in RealStar® S&T Influenza RT-PCR Kit 3.0 (altona 
Diagnostics) for the specific amplification and detection of seasonal Influenza A 
and pandemic H1N1 strains. 
 
 Target Sequence 5’-3’ Oligo  
 Matrix AGAGACTTGAAGATGTATTTGCTGGGAAGAT Probe 1  
 Matrix TCCTGCAAAGACACTTTCCAGT Probe 2  
 Matrix CAGGCCCCCTCAAAGC Primer 1  
 Matrix CGTCAGGCCTCCTCAAAGC Primer 2  
 Matrix ATTCCATGAGAGCCTCAAGATC Primer 3  
 
In this study, IC was added to the master mix as a qRT-PCR inhibition control because 
viral RNA extraction was performed at once for all of the experiments. The work was 
performed according to the manufacturer’s instructions (altona Diagnostics 2016). Am-
plification protocol can be seen in Table 7 and the full work protocol for the experiment 
in the Appendix 5. The whole set of different samples were added in one qRT-PCR 
experiment. The set up was with dilution series of influenza A and B (ATCC®), five 
different influenza strains from NATtrol™ FLU Verification Panel (ZeptoMetrix Corpora-
tion) samples (Table 13) and clinical samples 1-6 containing different influenza strains. 
 
Table 7. Amplification protocol used with RealStar® S&T Influenza RT-PCR Kit 3.0 (altona 
Diagnostics). 
 
 Step Stage Cycles Temp (°C) Time  
 Reverse transcription Hold 1 55 10 min  
 Denaturation Hold 1 95 2 min  
 
Amplification Cycling 45 
95 15 s  
 55 45 s  
 72 15 s  
 
7.4.4 RealStar® RSV RT-PCR Kit 1.0 (altona Diagnostics) 
 
This assay is designed for the detection of respiratory syncytial virus specific RNA. 
Furthermore, the test allows the differentiation between RSV subgroup A and RSV sub-
group B. Assay also includes IC to be used as a RT-PCR inhibition control and/or as a 
sample preparation procedure control. The probes were labelled with fluorescent re-
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porter and quencher dyes specific for their respective target. Fluorophore Cy5 was 
specific for RSV A, FAM for RSV B and JOE for IC. Amplification protocol can be seen 
in Table 8. 
 
Table 8. Amplification protocol used with RealStar® RSV RT-PCR Kit 1.0 (altona 
Diagnostics). 
 
 Step Stage Cycles Temp (°C) Time  
 Reverse transcription Hold 1 55 10 min  
 Denaturation Hold 1 95 10 min  
 
Amplification Cycling 45 
95 15 s  
 55 45 s  
 72 15 s  
 
In this study IC was added to the Master Mix and the experiment was performed ac-
cording to the manufacturer’s instructions (altona Diagnostics 2012). In the first phase 
of using RealStar® RSV RT-PCR Kit 1.0 (altona Diagnostics) the RT-PCR was run with 
dilution series of RSV A and B (ATCC) and set of other respiratory pathogens with 
NATtrol™ FLU Verification Panel (ZeptoMetrix Corporation) samples (Table 13). In the 
second phase clinical samples 7-10 containing RSV was added. The full work protocol 
for the experiment can be seen in the Appendix 5. 
 
7.4.5 RIDA®GENE Flu&RSV (R-Biopharm) 
 
The RIDA®GENE Flu&RSV (R-Biopharm) is the only multiplex qRT-PCR for both, in-
fluenza and RSV used in this study and it is designed for detection and differentiation 
of influenza A and B, as well as RSV. The probes were labelled with fluorescent re-
porter specific for their respective target. Fluorophore Cy5 was specific for influenza A, 
ROX for influenza B and FAM for RSV. Assay provides IC, which can be used as an 
internal control for sample preparation procedure and for determination of possible RT-
PCR inhibition control. Fluorophore specific for IC was VIC. Amplification protocol can 
be seen below in the Table 9: 
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Table 9. Amplification protocol used with RIDA®GENE Flu&RSV (R-Biopharm) kit. 
 
 Step Time Temp (°C) Cycles  
 Reverse transcription 10 min 58 1  
 Initial denaturation 1 min 95 1  
 Denaturation 15 s 95 
45 
 
 Annealing 30 s 55  
 
In this study, IC was added to the Master Mix and the experiment was performed ac-
cording to the manufacturer’s instruction (R-Biopharm 2014). Amplirun® influenza A H1 
RNA Control was diluted as a dilution series with influenza B, RSV A and B (ATCC) 
and set of other pathogens with NATtrol™ FLU Verification Panel (ZeptoMetrix Corpo-
ration) samples (Table 13) and real clinical samples 1-10 containing different influenza 
strains, as well as RSV. Full work protocol can be seen in the Appendix 5. 
 
7.4.6 R-DiaFlu (Diagenode) 
 
With the assay it is possible to detect and distinguish human influenza A and human 
influenza B. Target genes for influenza A are M1&2 and target gene for influenza B is 
NP. The probes were labelled with fluorescent reporter and quencher dyes specific for 
their respective target. Fluorophore FAM was specific for influenza A and fluorophore 
VIC for influenza B. 
 
In case of this protocol, manufacturer’s instruction were not completely followed, be-
cause it was the only qRT-PCR assay which is not designed to be used in neither Ap-
plied Biosystems® ViiA™ 7 Real-Time PCR System nor Applied Biosystems® 7500 
Real-Time PCR Systems. Instead, the qPCR instrument listed in the manual was Ap-
plied Biosystems® 7500 Fast Dx Real-Time PCR System, which is very similar to Ap-
plied Biosystems® 7500 Real-Time PCR Systems. Diagenode kit has been used be-
fore in Orion Diagnostica Oy with these PCR instruments and has been proved work-
ing. Except used qPCR instrument, work protocol was following the manufacturer’s 
instructions. Amplification protocol can be seen below in the Table 10. 
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Table 10. Amplification protocol used with R-DiaFlu (Diagenode) kit. 
 
 Step Time Temp (°C) Cycles  
 Reverse transcription 30 min 50 1  
 Activation (Tag) 10 min 95 1  
 Denaturation 15 s 95 
45 
 
 Annealing 30 s 55  
 Elongation 30 s 68  
 
The RT-PCR set up was with dilution series of Amplirun® Influenza A H1 RNA Control 
and influenza B (ATCC), set of NATtrol™ FLU Verification Panel (ZeptoMetrix Corpora-
tion) samples (Table 13) and clinical samples 1-6 containing different influenza strains. 
Full work protocol can be seen in the Appendix 5. 
 
7.5 qPCR instruments 
 
In this study, two of qPCR instruments were used including, Applied Biosystems® 
ViiA™ 7 Real-Time PCR System which uses ViiA™ 7 Software and Applied Biosys-
tems® 7500 Real-Time PCR Systems which uses 7500 Software v2.0.6. Selected 
qPCR instruments utilize different software even though both of them are provided by 
Thermo Fisher Scientific. 
 
qPCR instruments were chosen to this study based on manufacturer’s instruction of 
qRT-PCR kits. Manufacturers generally validate their assays for few different qPCR 
instruments. Moreover, general usage in the laboratory of Research and Development 
at Orion Diagnostica Oy contributed to the options. Tight schedule of the study made it 
impossible to rely on only one qPCR instrument. Despite different software used, qPCR 
programme and data pre-processing pipeline in both instruments were similar. 
 
8 Results 
 
The results of this study are explained in work order and demonstrated with tables and 
pictures obtained from qPCR platforms. Overview of all the results can be seen in Ta-
ble 12. 
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8.1 Quantitation 
 
Based on created standard curve with Genesig® pathogen assays (Primerdesign), 
number of copies per each extracted vRNA sample was determined (Table 11). Re-
sults can be seen in Table 10. Due to the delay in order of correct influenza A kit, ex-
tracted ATCC influenza A stock was not used. Sample was replaced with Vircell Am-
pliRun® Influenza A H1 RNA control which was diluted from lyophilized form to meet 
quantity of 10 000 cp/µL. 
 
Table 11. Results from quantitation of viral RNA with Genesig® qRT-PCR Pathogen kits 
(Primerdesign) presenting the number of copies per µL. 
 
 Pathogen Quantity (cp/µL)  
 Influenza B ATCC® VR-1813™ 1.81E+06  
 RSV A ATCC® VR-1540™ 1.33E+05  
 RSV B ATCC® VR-1400™ 8.46E+05  
 
Standard curve included 6 points of 10-fold dilution, each of them was duplicated. Re-
sults obtained from the standard curve showed that the assays could be used for quan-
titation of the target RNA. Regarding the influenza B, the slope was - 3.657 and the 
correlation R2 = 0.998. For RSV A the slope was − 4.009 and the correlation coefficient 
R2 = 0.999 of the standard curve. For RSV B the slope was - 4.348 and the correlation 
coefficient R2 = 0.998. R2 is a parameter, which indicates degree of overlap of data 
points with the standard curve. Values lower than 0.95 indicate no linear correlation 
between the Ct and the 10 log of the RNA concentration or that the reactions have not 
been pipetted accurately. (Eurogentec.) All the results were higher than 0.95 and there-
fore linear correlation between the Ct and the 10 log of the RNA occurred. 
 
8.2 Sensitivity and inclusivity 
 
Assay sensitivity was defined with 10-fold dilution series from extracted ATCC® patho-
gen samples. Dilution series was performed with starting quantity of 10 000 cp/µL up to 
1 cp/µL. All of the used kits, except RIDA®GENE Flu&RSV (R-Biopharm) met the 
highest possible sensitivity when there was detection in lowest dilution of 1 cp/µL. Re-
garding RIDA®GENE Flu&RSV (R-Biopharm), no amplification was detected in influ-
enza A. All the results from ATCC® sample dilutions can be viewed in Table 12. 
 
27 
  
When comparing the Ct values of all used qRT-PCR kits, it is clear that both, Re-
alStar® (altona Diagnostics) kits (Influenza S&T RT-PCR Kit 3.0 and RSV RT-PCR Kit 
1.0) performed the best because the Ct values were the lowest. This means, that the 
PCR product starts to form earlier, and therefore assay is more sensitive. RIDA®GENE 
Flu&RSV (R-Biopharm) kit did not detect the lowest quantity of influenza A (1 cp/µL) 
and the Ct values were worst among all used pathogens for the lowest dilutions (1 
cp/µL) from 31.8 – 37.6. Also, Genesig® Respiratory Syncytial Virus (all species) 
Standard Kit (Primerdesign) performed significantly worse particularly with detecting 
target RSV A with average 67.6 % difference in Ct values compared to RealStar® RSV 
RT-PCR Kit 1.0. Difference between RealStar® Influenza S&T RT-PCR Kit 3.0 and R-
DiaFlu (Diagenode) was not significant, however, consistently in favor of the RealStar® 
assays. 
 
Table 12. Comparison table of used qRT-PCR kits in order to evaluate sensitivity of the 
assays based on Ct values. 
 
Pathogen qRT-PCR Assay 
Influenza A RealStar Influenza 
3.0 (Ct) 
RidaGene Flu&RSV R-DiaFlu 
10^4 23.4 25.9 24.4 
10^3 26.2 29.4 27.6 
10^2 28.8 32.8 30.8 
10^1 31.7 37.7 35.3 
10^0 35.2 Undetermined 37.4 
Influenza A RealStar Influenza 
3.0 (Ct) 
RidaGene Flu&RSV 
(%) 
R-DiaFlu  
(%) 
10^4 23.4 10.6 4.1 
10^3 26.2 12.2 5.4 
10^2 28.8 13.9 6.9 
10^1 31.7 19.2 11.4 
10^0 35.2 Undetermined 6.3 
AVERAGE (%)  14.0 7.3 
Influenza B RealStar Influenza 
3.0 
RidaGene Flu&RSV R-DiaFlu 
10^4 20.6 25.4 20.8 
10^3 24.3 28.4 23.8 
10^2 27.2 31.2 27.3 
10^1 30.1 34.8 29.8 
10^0 32.3 37.4 33.7 
Influenza B RealStar Influenza 
3.0 (Ct) 
RidaGene Flu&RSV 
(%) 
R-DiaFlu  
(%) 
10^4 20.6 23.6 1.0 
10^3 24.3 16.8 -2.1 
10^2 27.2 14.7 0.1 
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10^1 30.1 15.8 -0.8 
10^0 32.3 15.8 4.4 
AVERAGE (%)  17.3 0.5 
RSV A RealStar RSV 1.0 
(Ct) 
RidaGene Flu&RSV Genesig RSV 
10^4 13.8 18.9 25.4 
10^3 16.8 22.2 29.3 
10^2 19.7 25.6 33.8 
10^1 23.6 29.1 37.4 
10^0 27.0 31.9 40.5 
RSV A RealStar RSV 1.0 
(Ct) 
RidaGene Flu&RSV 
(%) 
Genesig RSV  
(%) 
10^4 13.8 37.1 84.4 
10^3 16.8 32.1 73.9 
10^2 19.7 30.0 71.4 
10^1 23.6 23.0 58.4 
10^0 27.0 18.1 50.0 
AVERAGE (%)  28.1 67.6 
RSV B RealStar RSV 1.0 
(Ct) 
RidaGene Flu&RSV Genesig RSV 
10^4 20.8 21.4 26.7 
10^3 24.1 28.3 30.4 
10^2 27.7 31.0 34.3 
10^1 31.1 34.4 37.6 
10^0 33.9 37.6 41.7 
RSV B RealStar RSV 1.0 
(Ct) 
RidaGene Flu&RSV 
(%) 
Genesig RSV  
(%) 
10^4 20.8 3.3 28.8 
10^3 24.1 17.4 26.1 
10^2 27.7 11.8 23.7 
10^1 31.1 10.7 21.1 
10^0 33.9 11.0 23.2 
AVERAGE (%)  10.8 24.6 
 
Although the RealStar® RSV RT-PCR Kit 1.0 (altona Diagnostics) is able to distinguish 
RSV subgroups A and B, it might be somewhat less sensitive when detecting target 
RSV B. When analyzing the amplification curve, there was minor “crawling” detected in 
probe labelled with fluorophore specific to RSV B (FAM) when using dilution series of 
ATCC® RSV A samples (Figure 9). 
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Figure 9. Amplification plot from RealStar® RSV RT-PCR Kit 1.0 (altona Diagnostics). 
ATCC® RSV A and B samples with 10-fold dilution series. Results of both RSV A 
(blue) and RSV B (purple) displayed in channel specific for RSV B (FAM). 
 
The inclusivity of the qRT-PCR assays and possible cross-reaction between other res-
piratory pathogens were evaluated by their performance after adding nucleic acids from 
other common human respiratory pathogens using extracted NATtrol™ FLU Verifica-
tion Panel (ZeptoMetrix Corporation) samples (Table 13). The panel contained viral or 
bacterial particles and it contained six different influenza A virus strains, two influenza 
B strains, respiratory syncytial virus A, respiratory syncytial virus B, rhinovirus 1 A, 
parainfluenzavirus type 1, Echovirus Type 30, Coxsackievirus type A9, Mycoplasma 
pneumoniae strain M129, and Neisseria meningitidis Serogroup A.  
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Table 13. Inclusivity and possible cross-reactions of the used qRT-PCR kits were evaluated 
with NATtrol FLU verification panel containing other respiratory pathogens. IAV = 
influenza A, IBV = influenza B, RED = false positive, GREEN = false negative, 
GREY = was not tested. 
 
NATtrol Flu 
Verification 
Panel 
RealStar  R-DiaFlu  RidaGene   Genesig 
IAV 
IAV 
H1N
1 
IBV 
RSV 
A 
RSV 
B 
 
IAV IBV 
 
IAV IBV RSV 
 
RSV 
Rhinovirus  
Type 1A 
   - -         - 
M. Pneu-
moniae 
   - -         - 
N.Meningitidis    - -         - 
RSV A    - +         + 
RSV B    + -         + 
Echovirus  
Type 30 
   - -         - 
Parainfluenza 1    - -         - 
Influenza A  
H1N1 New Cal 
   - -     + - -  - 
Influenza A  
H3N2 Wiscon-
sin 
+ - -    + -  - - -   
Influenza A  
H1N1 09 Ca-
nada 
+ + -    + -  + - -   
Influenza A  
H1N1Brisbane 
+ - -    + -  + - -   
Influenza A  
H3N2 Brisbane 
+ - -    + -  + - -   
Influenza A 
H1N1 09 Ny 
- + +    + +  + - (+)   
Influenza B  
Florida 
   - -     + + +  - 
Influenza B  
Malaysia 
- - +    - +  - + -   
Coxsackievirus 
Type A9 
   - -         - 
 
False positive results were obtained in three qRT-PCR assays, RIDA®GENE Flu&RSV 
(R-Biopharm), RealStar® Influenza S&T RT-PCR Kit 3.0 (altona Diagnostics) and R-
DiaFlu (Diagenode). Regarding RealStar® assays (altona Diagnostics), all of the target 
RNA were detected correctly except influenza B virus, which incorrectly reported pres-
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ence of influenza A H1N1 09 Ny virus. Also there was a slight ambiguity with influenza 
A H1N1 Brisbane, which was detected only in influenza A channel, but not in the H1N1 
channel specifically designed for it. RSV A and RSV B were detected and divided into 
appropriate subgroups. Similarly, R-DiaFlu (Diagenode) reported detection of influenza 
A H1N1 09 on its influenza B specific channel. Otherwise, assigned target RNA was 
identified correctly. Genesig® Respiratory Syncytial Virus (all species) Standard Kit 
(Primerdesign) was able to detect the target RNA, even though it was not able to dis-
tinguish the subgroups of RSV and the results were positive for both, RSV A and RSV 
B sample. 
 
False negative results were obtained in two qRT-PCR assays, RIDA®GENE Flu&RSV 
(R-Biopharm) and RealStar® Influenza S&T RT-PCR Kit 3.0 (altona Diagnostics). In 
RIDA®GENE Flu&RSV (R-Biopharm) kit there was no detection of influenza A H3N2 
Wisconsin strain and with RealStar® Influenza S&T RT-PCR Kit 3.0 (altona Diagnos-
tics) probe specific for influenza A H1N1 did not detect influenza A H1N1 Brisbane 
strain. 
 
Regarding RIDA®GENE Flu&RSV (R-Biopharm), there was a lot more misdetection 
with target RNA, and cross-reactivity between respiratory pathogens occurred (Figure 
10). Influenza A H3N2 Wisconsin was incorrectly identified as influenza B and influenza 
B Florida as influenza A. RSV channel gave strong positive readings in influenza B 
Florida and weak positive readings in influenza A H1N1 09 NY. 
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Figure 10. Amplification plots from RIDA®GENE Flu&RSV (R-Biopharm) qRT-PCR viewed 
from different channels specific for different target RNA. Samples extracted from 
NATtrol™ FLU Verification Panel (ZeptoMetrix Corporation). 1 = Influenza A 
H1N1 Ny, 2 = Influenza A H1N1 09 Canada, 3 = Influenza B Florida, 4 = Influen-
za A H1N1 New Cal, 5 = Influenza A H3N2 Brisbane, 6 = Influenza A H1N1 Bris-
bane, 7 = Influenza B Florida.  
 
These findings suggest that the RealStar® assays (altona Diagnostics), R-DiaFlu (Dia-
genode) and Genesig® Respiratory Syncytial Virus (all species) Standard Kit (Pri-
merdesign) are relatively specific for their respective target. On the contrary, RI-
DA®GENE Flu&RSV (R-Biopharm) cannot be described very specific and cross-
reactions between respiratory pathogens occurred. 
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8.3 Clinical samples 
 
Last step in the process of evaluating used qRT-PCR assays was to compare their 
performance with real clinical samples, which were extracted from nasopharyngeal 
swabs or aspirates. The results are listed in table 14. Usually, it is difficult to analyse 
real clinical samples because of the uncertainty about their content, however these 
samples have been identified in sending laboratories with validated methods, and 
therefore this issue was not of our concern. 
 
Table 14. Results from qRT-PCR of clinical samples. 
 
Clinical sample qRT-PCR assay 
 RealStar Influenza 
S&T 3.0 
RidaGene Flu&RSV R-DiaFlu 
1 27.8 32.8 28.7 
2 27.4 28.9 27.8 
3 20.4 23.3 20.1 
4 26.5 32.5 26.4 
5 30.0 32.1 32.1 
6 32.2 38.2 34.9 
 RealStar Influenza 
S&T 3.0 (Ct) 
RidaGene Flu&RSV 
(%) 
R-DiaFlu  
(%) 
1 27.8 18.0 3.4 
2 27.4 5.4 1.2 
3 20.4 14.4 -1.6 
4 26.5 22.5 -0.4 
5 30.0 6.8 7.1 
6 32.2 18.8 8.6 
AVERAGE (%)  14.3 3.1 
 RealStar RSV 1.0 
(Ct) 
RidaGene Flu&RSV Genesig RSV 
7 18.0 23.6 24.1 
8 22.4 26.3 27.6 
9 26.3 29.8 31.2 
10 18.0 21.5 21.9 
 RealStar RSV 1.0 
(Ct) 
RidaGene Flu&RSV 
(%) 
Genesig RSV  
(%) 
7 18.0 30.9 33.7 
8 22.4 17.4 23.2 
9 26.3 13.2 18.7 
10 18.0 19.5 21.8 
AVERAGE (%)  20.2 24.3 
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All the clinical samples were detected correctly, although samples 5 (average Ct 31.41) 
and 6 (Average Ct 35.11) were weak in all assays. However, from earlier experiments 
with these clinical samples sample 6 was registered as a weak influenza B virus. Both 
RealStar® (altona Diagnostics) kits (Influenza S&T RT-PCR Kit 3.0 and RSV RT-PCR 
Kit 1.0) performed the best because the Ct values were the lowest. In this assessment 
RIDA®GENE Flu&RSV (R-Biopharm) and Genesig® Respiratory Syncytial Virus (all 
species) Standard Kit (Primerdesign) performed significantly worse particularly with 
detecting RSV clinical samples with 20.2 % and 24.3 % difference in Ct values on av-
erage compared to RealStar® RSV RT-PCR Kit 1.0. 
 
It is clear, that the RealStar® RSV RT-PCR Kit 1.0 (altona Diagnostics) performed sig-
nificantly better than RIDA®GENE Flu&RSV (R-Biopharm) or Genesig® Respiratory 
Syncytial Virus (all species) Standard Kit (Primerdesign). With clinical samples regis-
tered as Influenza A and B virus, difference between RealStar® Influenza S&T Kit 3.0 
(altona Diagnostics) and R-DiaFlu (Diagenode) was very small. R-DiaFlu (Diagenode) 
maybe transcends over the stronger samples, but in case of weaker samples, Re-
alStar® Influenza S&T Kit 3.0 (altona Diagnostics) is superior. 
 
8.4 Reliability of results 
 
Reliability of the results is ensured by following good laboratory practises and research 
ethics. Professional ethics is intended to carry out the study professionally, in order to 
obtain honest, reliable, high quality results. 
 
The experimental part of this thesis was carried out following the Orion Diagnostica Oy 
laboratory work instructions and aseptic approach was performed in order to avoid risk 
of contamination. During the work process no contamination was detected. All used 
laboratory equipment and facilities were cleaned as instructed before and after the 
work. Contamination of the reagents or samples was avoided by using appropriate la-
boratory clothing. Work with the samples and reagents was carried out in cold blocks or 
ice and long term storage of the used reagents was either in a freezer (- 20 °C) or in 
fridge temperature depending on manufacturers instruction. Used samples were al-
ways stored in - 70 °C before and after the use. Moreover, to avoid multiple unfreezing 
steps, after the extraction and quantitation samples were aliquoted to optimal amount. 
Therefore, for each experiment, samples were unfrozen only once. Traceability of the 
study was ensured by careful documentation of all of the experiments on the network 
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drives and in manual laboratory diaries. All the results were honestly obtained and re-
ported in this thesis. 
 
Reliability of the results from qRT-PCR assays was evaluated after each experiment. 
Two negative controls were included in each experiment and were confirmed not to be 
amplified after qRT-PCR assay. This was to detect possible contamination of the rea-
gents while setting up the assay. Moreover, two positive controls were included in qRT-
PCR run to ensure that primers and probes of the used assay were detecting their re-
spective target. All the processes from the RNA extraction to the qRT-PCR were car-
ried out according to the manufacturer’s instructions as much as it was possible with 
given time and resources.  
 
All the negative and positive controls worked correctly and based on these parameters 
the results can be considered reliable. However, repeatability and comparability have 
to be discussed when all of the qRT-PCR assays were tested only once. Therefore, 
statistics from the assays was relatively minor. Because of the limited data, the results 
are only suggestive. More data and testing are needed for reliable statistical analysis, 
for evaluating the assays and for reliable conclusions. 
 
9 Discussion 
 
The aim of the study was to set up several commercially available qRT-PCR kits for 
diagnosis of RSV and influenza viruses. Experiments were designed to evaluate the 
sensitivity and inclusivity of the qRT-PCR assays, as well as possible cross-reactions 
with other respiratory tract pathogens. Moreover, other features were taken into con-
sideration during the process, such as the ease of use and the time of delivery. There 
were significant differences in the performance between used qRT-PCR assays.  
 
All the used qRT-PCR kits performed with highest possible sensitivity except Ri-
da®Gene Flu&RSV (R-Biopharm) where false negative result was obtained in lowest 
dilution from ATCC® sample dilution series. The best results on the other hand, were 
obtained when comparing the Ct values, Real®Star Influenza S&T RT-PCR Kit 3.0 and 
RealStar® RSV RT-PCR 1.0 (altona Diagnostics). The differences between Ct values 
deviated from 0.5 % up to 67.6 % on average. More significant results were obtained 
with tests containing samples from NATtrol™ FLU Verification Panel (ZeptoMetrix Cor-
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poration). With pathogens from the panel there were abundant cross-reactions be-
tween influenza virus strains and even different respiratory pathogens. RIDA®GENE 
Flu&RSV (R-Biopharm) kit had probe specific for RSV, however it additionally gave 
weak positive result for influenza A H1N1 09 NY strain and strong positive result in 
Influenza B Florida strain. Also Real®Star Influenza S&T RT-PCR Kit 3.0 (altona Diag-
nostics) and R-DiaFlu (Diagenode) showed positive results for influenza A H1N1 09 NY 
strain in channel specific for influenza B. It was interesting to observe, that in all of the 
mentioned kits the influenza A H1N1 09 NY strain was detected incorrectly. Before 
accusing contamination during the extraction process, the results showed that the de-
tection was not consistent. With Real®Star Influenza S&T RT-PCR Kit 3.0 (altona Di-
agnostics) and R-DiaFlu (Diagenode) the detection was done in influenza B specific 
channel, but with RIDA®GENE Flu&RSV (R-Biopharm) kit it was negative for influenza 
B and positive for RSV. Therefore, specificity of the assays can be questioned. qRT-
PCR assays are limited by the quality of the chosen primers and probes. They have to 
be not only sensitive enough to match all target RNA, but also specific enough to ex-
clude all others. 
 
In previous study by Esposito et al. (2016), RIDA®GENE Flu & RSV (R-Biopharm) kit 
was shown to be highly sensitive and specific, unlike in my study. Assay was evaluated 
to be used in routine practise and samples used in that study were obtained from hos-
pitalized patients with significant symptoms of either lower or upper respiratory infec-
tion. Also the sensitivity of the assay was calculated using synthetic RNA fragment and 
the results were ≥ 50 RNA copies per reaction or 10 copies/μL. Therefore, the results 
are not fully comparable with this study where lowest dilution to measure sensitivity 
was 1 copy/ μL. Also ReaStar® Influenza S&T RT-PCR Kit 3.0 (altona Diagnostics) 
was declared as an assay with high sensitivity in the previous study of Hatchette et al. 
(2013), although no specificity was tested. For that reason, it is difficult to evaluate if 
the cross-reaction is a problem with this study or the specificity of the assays is moder-
ate in general. The problem with moderate specificity comes when qRT-PCR assay is 
used as a reference method for other gene amplification technology. At times clinical 
samples with no information of pathogens are screened and if qRT-PCR assay gives 
false negative or false positive results, it is impossible to know whether qRT-PCR or 
the new technology is responsible for the problem. 
 
All of the selected qRT-PCR kits contained materials for Master Mix in different forms, 
positive control or positive controls together with negative control. Only Genesig® Res-
37 
  
piratory Syncytial Virus (all species) Standard Kit (Primerdesign) was to be combined 
with separate Master Mix reagent (oasigTM Lyophilised OneStep or PrecisionTM 
OneStep 2x qRT-PCR MasterMix) and it did not contain internal control unlike other 
qRT-PCR assays. Preparation of the reaction mix was relatively simple for all used 
assays, although some of them required more steps and was not always straightfor-
ward. For instance, in Genesig® pathogen kits the Master Mix was in lyophilized form 
in a glass ampule. After re-suspending the Master Mix with the re-suspension buffer, 
appropriate amount of the Master Mix had to pipet from the glass ampule to the centrif-
ugation tube with primer/probe mix and RNAse/DNAse free water. If the required vol-
ume was higher than 200 µL, the pipette tip was too big and the sample had to be pi-
petted twice with smaller volume pipette.  
 
Based on the results, it can be concluded that the best qRT-PCR assays for diagnos-
tics of influenza viruses and RSV were RealStar® Influenza S&T RT-PCR Kit 3.0 and 
RealStar® RSV RT-PCR Kit 1.0 (altona Diagnostics). The aforementioned assays met 
high sensitivity and RealStar® RSV RT-PCR Kit 1.0 (altona Diagnostics) also specifici-
ty criteria. Both RealStar® assays included IC and they were easy to use. RealStar® 
Influenza S&T RT-PCR Kit 3.0 can also distinguish pandemic influenza A H1N1 strain 
from seasonal influenza A, although there was some mismatch detected between pan-
demic influenza strain and influenza B. Moreover, these assays are CE-marked and 
can be used in in vitro diagnostics. Only clear disadvantage for this assay was that it 
requires 10 µL sample or control, whereas other assays require only 5 µL. This is es-
pecially important for research applications where clinical samples are not routinely 
available and reagents are usually harder to obtain and are relatively expensive. Re-
gardless of these disadvantages, usability of these qRT-PCR assays is considerably 
better than with other assays. 
 
In this study, the results were presented statistically in comparative table based on the 
Ct values obtained from the qRT-PCR. Ct values were also compared between qRT-
PCR kits and presented as average percentage difference between Ct values. Gener-
ally, comparing the Ct values is not a standard method because amplification is loga-
rithmic. However, in this study comparison was done this way to elucidate raw data. 
 
The follow-up step would be to test RealStar® pathogen Kits with Orion Diagnostica Oy 
samples processed to be used in freeze-dried SIBA® reactions. Regrettably, as some 
of the extracted ATCC® RNA samples were weaker than first expected, we were not 
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able to determine the limit of detection in high concentrations. Also, the obtained data 
were relatively small because of the delay in order of correct Genesig® Influenza H1N1 
Kit (Primerdesign). First ordered Kit was designed for influenza A H1 and it is targeted 
to M2 rather than M1 found in H1N1 specifically.  Delay cost valuable time to test qRT-
PCR Kits when extracted influenza A samples (ATCC®) could not be quantitated.  As 
the subject could have expanded to almost unlimited, this effectively restricted the time 
and moreover, the used qRT-PCR Kits. I wish I had more time to carry out more tests 
with various qRT-PCR Kits and with different features. In the beginning I had more 
qRT-PCR kits to test and all together eight of them were set up. Two of eight did not 
work even with best effort to contact manufacturer and were excluded from the thesis. 
First kit was the Genesig® influenza A subtype H1 (Primerdesign) which turned out to 
be wrong type for tested strains and second was LyraTM Influenza A+B assay (Quidel®) 
with the FDA approval. It was unfortunate that the only qRT-PCR Kit with FDA approval 
did not work.  
 
Even though the subject of the study was to test different qRT-PCR Kits, the motive 
was to find reference method for tests based on SIBA® technology. Faster and more 
sensitive methods for diagnosing of influenza viruses and RSV are necessary. Alt-
hough, majority of respiratory tract infections are of viral etiology, they account for 
three-quarters of all antibiotic prescriptions. Antimicrobial drugs may have reduced the 
threat posed by infectious diseases; however, these advantages are now endangered 
by the emergence and spread of microbes that are resistant to effective first-choice 
drugs. (Low 2008.) Today, while fighting with increasing resistance to antibiotics, it is 
progressively important to develop sensitive and accurate infection diagnostic methods 
for infectious diseases. When source of the infection can be reliably diagnosed, correct 
treatment with antimicrobial drugs or antiviral drugs can be prescribed.  
 
For influenza viruses, the most important benefits of rapid POC molecular diagnostics 
are better infection control over epidemic and pandemic influenza strains and lowering 
the hospitalization rate. RSV infections seem inevitable when virtually everyone be-
comes infected by the age of two therefore, it is reasonable to think benefits of early 
diagnostics of the infection. It has been shown in previous studies, that there is a posi-
tive correlation between severe RSV bronchiolitis and increase of early wheezing, 
asthma and even allergic sensitization later in life. Therefore, early diagnosis might 
reduce these risks when treatment with monoclonal antibodies can be started at earli-
est possible. (Blanken et al. 2013.) 
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Although, new period has begun in the ongoing development of POC molecular testing 
and diagnosis, surely the same challenges will have to be faced and similar problems 
overcome as in case of any other POC tests. While the molecular diagnostics show 
more sensitivity and specificity, there is higher chance of contamination and mistakes 
in pre-analytical phase. Careful introduction among users becomes more and more 
significant. Eboigbodin et al. (2016) are expecting the use molecular methods outside 
of centralized laboratories into smaller units, or even domestic households. 
 
Along with this project, I created work instructions and comparison table for the used 
qRT-PCR assays to facilitate their use at Orion Diagnostica Oy. This reduces the time 
of assay set up when new user can follow the shorter instructions. This project at Orion 
Diagnostica Oy was enormously instructive and advantageous, because throughout the 
process I learned new techniques and methods. I am very satisfied with my new skills 
and I feel I received good skills for the future. In addition, the project helped me to de-
velop practical skills important in laboratory environment work and gave me confidence 
to work more independently. At times, I had to tolerate uncertainty, find answers inde-
pendently directly from the manufacturers and ask help, but as a reward I achieved 
valuable work experience in this field of research. 
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Appendix 1. Work protocol for extraction of ATCC and NATtrol™ FLU Veri-
fication Panel with QIAamp® Viral RNA Mini Kit. 
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Appendix 2. Work protocol for RNA extraction from clinical samples with 
QIAamp® Viral RNA Mini Kit. 
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Appendix 3. Content of the qRT-PCR kits: used reagents. 
 
Genesig Respiratory Syncytial virus (all species) Standard Kit: 
 
 
 
Genesig Human Influenza B virus: 
 
 
 
Oasig lyophilized OneStep qRT-PCR Mastermix: 
 
Reagent name Batch 
Lyophilized  Mastermix  
Lyophilized ROX OAS149 
Re-suspension buffer OAS166 
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RealStar Influenza S&T RT-PCR Kit 3.0: 
 
 
 
RealStar RSV RT-PCR Kit 1.0: 
 
 
 
RidaGene Flu&RSV: 
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R-DiaFlu: 
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Appendix 4. Quantitation of influenza B and RSV A and B: results and 
work protocols. 
 
Influenza B: 
Genesig® Standard Kit: human influenza B virus (Primerdesign™) 
 
Master Mix was not included to kit contents and it was reconstituted from oasigTM Ly-
ophilized OneStep or PrecisionTM OneStep 2x qRT-PCR MasterMix. 
 
Master Mix 
1. For each glass ampule; Re-suspend lyophilized OneStep Mastermix in 
525 µl of re-suspension buffer. 
2. Add ROX if required following instructions below: 
 
Real-time PCR Platform ROX re-suspension vo-
lume 
ROX addition per am-
pule 
Applied biosystems 7700, 
7000, and 7900, 7300, 
StepOne, StepOnePLUS and 
ViiA7 platforms, Roche capil-
lary Lightcyclers. 
100 20 
All Stratagene platforms 200 15 
Applied biosystems 7500 plat-
form 
700 10 
All Other Machines Not required Not required 
 
4. Re-suspend the lyophilized ROX (BROWN) in the correct volume of 
re-suspension buffer (table below) 
5. Add re-suspended ROX to each ampule at the correct level 
 
Reconstitution protocol for lyophilized primer and probe mix: 
 
1 Pulse-spin each tube in a centrifuge before opening. 
2. Reconstitute the positive control template in the template preparation 
buffer supplied, according to the table below: 
 
 
Appendix 4 
  2 (8) 
 
  
Component – resuspend in wa-
ter 
Volume (µL) 
fluB primer/probe mix 165 
fluB RT primer mix 165 
 
Reconstitution protocol for positive control template/standard curve: 
 
1 Pulse-spin each tube in a centrifuge before opening. 
2. Reconstitute the positive control template adding 500 µL of template 
preparation buffer supplied. 
3. Vortex the tube thoroughly. 
 
Standard curve dilution series: 
 
1. Pipette 90 µl of template preparation buffer into 5 tubes and label 2-6. 
2. Pipette 10 µl of Positive Control template (RED) into tube 2. 
3. Vortex thoroughly. 
4. Change pipette tip and pipette 10 µl from tube 2 into tube 3. Vortex thoroughly. 
5. Repeat steps 4 and 5 to complete the dilution series. 
 
 
Standard curve 
Copy number per 
µL 
 
 Tube 1 Positive control (RED) 2 x 10
^5
  
 Tube 2 2 x 10
^4
  
 Tube 3 2 x 10
^3
  
 Tube 4 2 x 10
^2
  
 Tube 5 20  
 
Sample dilution series: 
1:10 dilution from 10^5 cp/µL 
1. Pipette 45 µL RNAase free water 
2. Pipette 5 µL sample 
3. Change pipette tip and pipette 5 µL from10^4 tube to 10^3 tube 
4. Continue to get dilutions of 10^1, 10, 1 (cp/µL) 
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Reaction mix: 
 
Reagent Volume/ 1 reacti-
on (µL) 
Volume/ 25 reactions 
(µL) 
Oasig OneStep gRT-PCR Mas-
termix 
10 20 
fluB primer/probe mix 1 15 
RNAse/DNAse free water 4 10 
Total Volume 15 375 
 
Reaction setup: 
 
 µL 
Master Mix 20 
Sample or control 5 
Total Volume 25 
 
Amplification protocol: 
 
 Step Time Temp (°C) Cycles  
 Reverse transcription 10 min 55 1  
 Enzyme activation 2 min 95 1  
 Denaturation 10 s 95 
50 
 
 Data collection 60 s 60  
 
Results: 
Estimated virus concentration based on qRT-PCR results was 1808820.313 copies/µL. 
62 µL of sample was diluted in 1060 µL of RNAse-free water in order to get concentra-
tion of 100000 copies/µL. After this the sample was aliquoted into 1.5 ml microcentri-
fuge tubes and stored in - 70°C. 
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Raw data: 
 
Sample 
Name CT Ct Mean Ct SD Quantity 
Quantity 
Mean 
INF B 1:10 19,193 19,130 0,089 180 882,031 188 356,797 
STANDARD 18,844 19,117 0,386 200 000,000 
 STANDARD 33,964 33,847 0,165 20,000 
 INF B 1:10 19,066 19,130 0,089 195 831,563 188 356,797 
STANDARD 19,390 19,117 0,386 200 000,000 
 STANDARD 33,730 33,847 0,165 20,000 
 INF B 1:100 22,672 22,647 0,036 20 347,354 20 678,205 
STANDARD 22,793 22,808 0,020 20 000,000 
 STANDARD 35,184 37,400 3,134 2,000 
 INF B 1:100 22,621 22,647 0,036 21 009,057 20 678,205 
STANDARD 22,822 22,808 0,020 20 000,000 
 STANDARD 39,617 37,400 3,134 2,000 
 INF B 
1:1000 26,357 26,320 0,052 2 012,562 2 059,685 
STANDARD 26,121 26,109 0,018 2 000,000 
 NEGATIVE Undetermined 
    INF B 
1:1000 26,284 26,320 0,052 2 106,807 2 059,685 
STANDARD 26,096 26,109 0,018 2 000,000 
 NEGATIVE Undetermined 
    INF B 
1:10000 30,003 29,795 0,294 203,963 234,351 
STANDARD 29,894 29,921 0,038 200,000 
 INF B 
1:10000 29,587 29,795 0,294 264,739 234,351 
STANDARD 29,948 29,921 0,038 200,000 
  
RSV A and B: 
Genesig® respiratory syncytial virus (all species) Standard Kit 
 
Master Mix was not included to kit contents and it was reconstituted from oasigTM Ly-
ophilized OneStep or PrecisionTM OneStep 2x qRT-PCR MasterMix. 
 
Master Mix 
1. For each glass ampule; Re-suspend lyophilized OneStep Mastermix in 
525 µl of re-suspension buffer. 
2. Add ROX if required following instructions below: 
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Real-time PCR Platform ROX re-suspension vo-
lume 
ROX addition per ampu-
le 
Applied biosystems 7700, 
7000, and 7900, 7300, 
StepOne, StepOnePLUS and 
ViiA7 platforms, Roche capil-
lary Lightcyclers. (RSV A) 
100 20 
All Stratagene platforms 200 15 
Applied biosystems 7500 plat-
form (RSV B) 
700 10 
All Other Machines Not required Not required 
 
4. Re-suspend the lyophilised ROX (BROWN) in the correct volume of 
re-suspension buffer (table below) 
5. Add re-suspended ROX to each ampule at the correct level 
 
Reconstitution protocol for lyophilized primer and probe mix: 
 
1 Pulse-spin each tube in a centrifuge before opening. 
2. Reconstitute the positive control template in the template preparation 
buffer supplied, according to the table below: 
 
Component – resuspend in wa-
ter 
Volume (µL) 
RSV_spp primer/probe mix 165 
RSV_spp RT primer mix 165 
 
Reconstitution protocol for positive control template/standard curve: 
 
1 Pulse-spin each tube in a centrifuge before opening. 
2. Reconstitute the positive control template adding 500 µL of template 
preparation buffer supplied. 
3. Vortex the tube thoroughly. 
 
Standard curve dilution series: 
 
1. Pipette 90 µl of template preparation buffer into 5 tubes and label 2-6. 
2. Pipette 10 µl of Positive Control template (RED) into tube 2. 
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3. Vortex thoroughly. 
4. Change pipette tip and pipette 10 µl from tube 2 into tube 3. Vortex thoroughly. 
5. Repeat steps 4 and 5 to complete the dilution series. 
 
 
Standard curve 
Copy number per 
µL 
 
 Tube 1 Positive control (RED) 2 x 10
^5
  
 Tube 2 2 x 10
^4
  
 Tube 3 2 x 10
^3
  
 Tube 4 2 x 10
^2
  
 Tube 5 20  
 
Sample dilution series: 
1:10 dilution from 10^5 cp/µL 
1. Pipette 45 µL RNAse free water 
2. Pipette 5 µL sample 
3. Change pipette tip and pipette 5 µL from10^4 tube to 10^3 tube 
4. Continue to get dilutions of 10^1, 10, 1 (cp/µL) 
 
Reaction mix: 
 
Reagent Volume/ 1 reaction 
(µL) 
Volume/ 25 reactions 
(µL) 
Oasig OneStep gRT-PCR Mas-
termix 
10 20 
RSV_spp primer/probe mix 1 15 
RNAse/DNAse free water 4 10 
Total Volume 15 375 
 
Reaction setup: 
 
 µL 
Master Mix 20 
Sample or control 5 
Total Volume 25 
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Amplification protocol: 
 
 Step Time Temp (°C) Cycles  
 Reverse transcription 10 min 55 1  
 Enzyme activation 2 min 95 1  
 Denaturation 10 s 95 
50 
 
 Data collection 60 s 60  
 
Results: 
Estimated virus concentration based on qRT-PCR results was for RSV A 132979.25 
copies/µL. 68 µL of sample was diluted in 22 µL of RNAse-free water in order to get 
concentration of 100000 copies/µL.  
 
As for the RSV B, the result was 845853.75 copies/µL. 71 µL of sample was diluted in 
529 µL of RNAse-free water in order to get concentration of 100000 copies/µL. 
 
After quantitation and dilution, the samples were aliquoted into 1.5 ml microcentrifuge 
tubes and stored in - 70°C. 
 
Raw data (RSV A): 
 
Sample 
Name CT Ct Mean Ct SD Quantity 
Quantity 
Mean 
RSV A 1:10 26,204 26,766 0,795 17 463,584 13 297,925 
Standards 21,844 21,849 0,008 200 000,000 
 Standards 37,592 37,991 0,565 20,000 
 RSV A 1:10 27,328 26,766 0,795 9 132,266 13 297,925 
Standards 21,855 21,849 0,008 200 000,000 
 Standards 38,391 37,991 0,565 20,000 
 RSV A 1:100 31,516 31,405 0,157 815,811 871,375 
Standards 26,187 26,125 0,087 20 000,000 
 Standards 41,697 41,885 0,267 2,000 
 RSV A 1:100 31,295 31,405 0,157 926,938 871,375 
Standards 26,064 26,125 0,087 20 000,000 
 Standards 42,074 41,885 0,267 2,000 
 RSV A 
1:1000 35,951 35,589 0,512 63,209 79,588 
Standards 29,927 29,964 0,052 2 000,000 
 Negative Undetermined 
    RSV A 
1:1000 35,227 35,589 0,512 95,966 79,588 
Standards 30,000 29,964 0,052 2 000,000 
 Negative Undetermined 
    RSV A 39,138 39,375 0,335 10,057 8,856 
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1:10000 
Standards 33,971 33,929 0,059 200,000 
 RSV A 
1:10000 39,612 39,375 0,335 7,655 8,856 
Standards 33,887 33,929 0,059 200,000 
  
Raw Data (RSV B): 
 
Sample Name Cт Cт Mean Cт SD Quantity 
Quantity 
Mean 
RSV B 1:10 21,7222595 21,78255 0,08527 87297,60938 84585,375 
Standard 20,0803051 20,0279 0,074106 200000 
 Standard 37,9675484 37,594 0,528277 20 
 RSV B 1:10 21,8428497 21,78255 0,08527 81873,14844 84585,375 
Standard 19,9755039 20,0279 0,074106 200000 
 Standard 37,2204514 37,594 0,528277 20 
 RSV B 1:100 26,5688782 26,46874 0,141619 6625,997559 6998,472656 
Standard 24,5385418 24,68242 0,203478 20000 
 Standard 41,4561996 41,71004 0,358986 2 
 RSV B 1:100 26,3685989 26,46874 0,141619 7370,947266 6998,472656 
Standard 24,8263035 24,68242 0,203478 20000 
 Standard 41,9638824 41,71004 0,358986 2 
 RSV B 1:1000 30,9605942 30,64608 0,444785 640,6189575 767,9168701 
Standard 28,7507896 28,77447 0,033492 2000 
 
      RSVB1:1000 30,3315735 30,64608 0,444785 895,2147217 767,9168701 
Standard 28,7981548 28,77447 0,033492 2000 
 
      RSVB 1:10000 34,5868416 34,47871 0,152913 93,06798553 98,74144745 
Standard 32,8781204 33,11982 0,341812 200 
 NEG Undetermined 
    RSVB 1:10000 34,3705902 34,47871 0,152913 104,4149094 98,74144745 
Standard 33,361515 33,11982 0,341812 200 
 NEG Undetermined 
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Appendix 5. qRT-PCR protocols of used kits. 
 
RealStar Influenza S&T RT-PCR 3.0 Kit 
 
Primers and probes: 
 
Master Mix setup: 
reagent Volume/1 reaction Volume/49 reactions 
Master A 5 245 
Master B 10 490 
Internal Control 1 49 
Total Volume of the Master Mix 16 784 
 
Sample dilution series: 
1:10 dilution from 10^5 cp/µL 
1. Pipette 45 µL RNAase free water 
2. Pipette 5 µL sample 
3. Change pipette tip and pipette 5 µL from10^4 tube to 10^3 tube 
4. Continue to get dilutions of 10^1, 10, 1 (cp/µL) 
 
Reaction setup/well: 
Master Mix 15 
Sample or control 10 
Total Volume 25 
 
qRT-PCR protocol: 
 Step Stage Cycles Temp (°C) Time  
 Reverse transcription Hold 1 55 10 min  
 Denaturation Hold 1 95 2 min  
 
Amplification Cycling 45 
95 15 s  
 55 45 s  
 72 15 s  
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Fluorescent dyes 
INF A Cy5 
INF B ROX 
H1N1nv FAM 
IC JOE 
Quencher: NONE 
 
RealStar RSV RT-PCR Kit 1.0 
 
Master Mix setup: 
reagent Volume (µL)/1 reaction Volume/49 reac-
tions 
Master A 5 245 
Master B 10 490 
Internal Control 1 49 
Total Volume of the Master Mix 16 784 
 
Sample dilution series: 
1:10 dilution from 10^5 cp/µL 
1. Pipette 45 µL RNAase free water 
2. Pipette 5 µL sample 
3. Change pipette tip and pipette 5 µL from10^4 tube to 10^3 tube 
4. Continue to get dilutions of 10^1, 10, 1 (cp/µL) 
 
Reaction setup/well: 
Master Mix 15 
Sample or control 10 
Total Volume 25 
 
qRT-PCR protocol: 
 Step Stage Cycles Temp (°C) Time  
 Reverse transcription Hold 1 55 10 min  
 Denaturation Hold 1 95 10 min  
 
Amplification Cycling 45 
95 15 s  
 55 45 s  
 72 15 s  
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Fluorescent dyes: 
INF A Cy5 
INF B FAM 
IC JOE 
Quencher: NONE 
 
RidaGene FLU&RSV 
 
Master Mix setup: 
reagent Volume (µL)/1 reaction Volume/85 reactions 
Reaction Mix 12.5 1062.5 
Pp Mix 6.9 586.5 
Enzyme Mix 0.7 59.5 
Internal Control 1 85 
Total Volume of the Master Mix 21.1 1793.5 
 
Sample dilution series: 
1:10 dilution from 10^5 cp/µL 
1. Pipette 45 µL RNAase free water 
2. Pipette 5 µL sample 
3. Change pipette tip and pipette 5 µL from10^4 tube to 10^3 tube 
4. Continue to get dilutions of 10^1, 10, 1 (cp/µL) 
 
Reaction setup: 
 µL 
Master Mix 20 
Sample or control 5 
Total Volume 25 
 
qRT-PCR protocol: 
 Step Time Temp (°C) Cycles  
 Reverse transcription 10 min 58 1  
 Initial denaturation 1 min 95 1  
 Denaturation 15 s 95 
45 
 
 Annealing 30 s 55  
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Fluorescent dyes: 
RSV FAM 
ICR VIC 
Flu B ROX 
Flu A Cy5 
Quencher: NONE 
 
R-DiaFlu 
 
Master Mix setup: 
reagent Volume (µL)/1 reaction Volume/52 reactions 
Optima AB Master Mix 4X RNA 6.25 325 
PPpathogen (Flu A/B Probes and 
primers) 
2.5 130 
H2O 11.25 585 
Total Volume of the Master Mix 20 1040 
 
Sample dilution series: 
1:10 dilution from 10^5 cp/µL 
1. Pipette 45 µL RNAase free water 
2. Pipette 5 µL sample 
3. Change pipette tip and pipette 5 µL from10^4 tube to 10^3 tube 
4. Continue to get dilutions of 10^1, 10, 1 (cp/µL) 
 
Reaction setup: 
 µL 
Master Mix 20 
Sample or control 5 
Total Volume 25 
 
qRT-PCR protocol: 
 Step Time Temp (°C) Cycles  
 Reverse transcription 30 min 50 1  
 Activation (Tag) 10 min 95 1  
 Denaturation 15 s 95 
45 
 
 Annealing 30 s 55  
 Elongation 30 s 68  
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Appendix 6. qRT-PCR kit comparison table 
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